# Mepolizumab

## Nucala 100mg inj

#### 本院臨採清單

| 藥品代碼       | INUC                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
|:---------------|:----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 適應症         | severe refractory eosinophilic asthma                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| 用法用量       | Asthma: Adults and Age >12 years old: 100 mg administered by subcutaneous (SC) injection once every 4 weeks. Age 6-11 years old: 40 mg administered by subcutaneous (SC) injection once every 4 weeks. Eosinophilic granulomatosis with polyangiitis: Adults and Age >12 years old: 300 mg administered by subcutaneous (SC) injection once every 4 weeks.                                                                                                                                                                                                                                                                                                                              |
| 肝功能異常     | 無需調整劑量                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| 腎功能異常     | 無需調整劑量                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| 禁忌           | Hypersensitivity to mepolizumab or any component of the formulation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| 副作用         | >10%: Central nervous system: Headache (19%) Local: Injection site reaction (8% to 15%) 1% to 10%: Central nervous system: Fatigue (5%) Dermatologic: Eczema (3%)， pruritus (3%) Gastrointestinal: Upper abdominal pain (3%) Genitourinary: Urinary tract infection (3%) Hypersensitivity: Hypersensitivity reaction (eosinophilic granulomatosis: 4%)， angioedema (eosinophilic granulamatosis: 1%) Immunologic: Immunogenicity (asthma: 6%， eosinophilic granulomatosis: <2%; neutralizing: <1%) Infection: Influenza (3%) Neuromuscular & skeletal: Back pain (5%)， muscle spasm (3%) Frequency not defined: Hypersensitivity: Delayed hypersensitivity Infection: Herpes zoster |
| 孕期用藥建議   | Human data suggest low risk                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| 哺乳期用藥建議 | No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |

